# 2026年2月17日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 探索隐源性新发难治性癫痫持续状态患者演变为耐药性癫痫的路径。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41697646)
**期刊：** Epilepsia
**PMID：** 41697646
**DOI：** 10.1002/epi.70146

### 第一部分 原文与翻译

**英文原标题：** Exploring pathways leading to drug-resistant epilepsy for patients with cryptogenic new onset refractory status epilepticus.

> **英文摘要：**
> OBJECTIVE: Cryptogenic new onset refractory status epilepticus (cNORSE) carries high risks of long-term disability and post-NORSE epilepsy, but mechanisms remain unclear. We aimed to assess the predictive value of inflammatory and brain injury biomarkers and determine whether immune disturbances persist in the chronic phase. METHODS: We enrolled 93 cNORSE patients from the Pitié-Salpêtrière Hospital and the Yale NORSE/FIRES biorepository (2013-2025). Serum and cerebrospinal fluid (CSF) samples were collected during status epilepticus (SE), with outcomes assessed 6-12 months after resolution. To investigate post-cNORSE epilepsy, we compared 39 post-cNORSE patients (25 with paired acute samples) to 40 patients with temporal lobe epilepsy due to hippocampal sclerosis (TLE-HS) and 20 with chronic immune-mediated encephalitis. RESULTS: During cNORSE, elevated innate cytokines (serum CXCL8, CCL2; CSF IL-6, CXCL8, CCL2, MIP-1α, G-CSF) and brain injury biomarkers (serum and CSF neurofilament light chain [NfL], CSF neuron-specific enolase) correlated with worse functional outcomes. Multivariate models demonstrated that adding serum NfL to cytokines improved poor outcome prediction (area under the curve = .75). In contrast, no acute biomarker predicted post-cNORSE epilepsy, which was instead associated with prolonged SE, magnetic resonance imaging abnormalities, and the need for more intensive treatment. In paired analyses, most serum cytokines normalized during the chronic phase, particularly IL-6, IL-10, and IL-1β, although new adaptive immune disturbances (IL-17A, IL-12p70, TNFα) appeared in 20% of patients. No chronic elevations of innate cytokines were observed in post-cNORSE patients. Conversely, elevated age-adjusted NfL levels were more frequent in post-cNORSE epilepsy (64%) than encephalitis (45%) and TLE-HS (20%), (p < .001), with elevated NfL levels correlating with poor functional outcomes (p = .019). SIGNIFICANCE: Innate immune activation is a hallmark of acute cNORSE but largely resolves in the chronic phase, arguing against persistent innate inflammation as the driver of post-cNORSE epilepsy. In contrast, persistently elevated NfL levels suggest ongoing axonal injury, potentially contributing to poor outcomes. Integrating inflammatory and neuroaxonal injury biomarkers may improve risk stratification and guide long-term management.

> **中文摘要：**
> 目的：隐源性新发难治性癫痫持续状态（cNORSE）具有长期残疾和 NORSE 后癫痫的高风险，但其机制尚不明确。本研究旨在评估炎症和脑损伤生物标志物的预测价值，并确定慢性期是否存在持续的免疫紊乱。方法：我们招募了来自 Pitié-Salpêtrière 医院和耶鲁大学 NORSE/FIRES 生物样本库（2013-2025 年）的 93 名 cNORSE 患者。在癫痫持续状态（SE）期间收集血清和脑脊液（CSF）样本，并在 SE 解决后 6-12 个月评估结局。为了研究 cNORSE 后癫痫，我们将 39 名 cNORSE 后患者（其中 25 名具有配对的急性期样本）与 40 名因海马硬化导致的颞叶癫痫（TLE-HS）患者以及 20 名慢性免疫介导的脑炎患者进行了比较。结果：在 cNORSE 期间，先天性细胞因子水平升高（血清 CXCL8、CCL2；CSF IL-6、CXCL8、CCL2、MIP-1α、G-CSF）和脑损伤生物标志物（血清和 CSF 神经丝轻链 [NfL]、CSF 神经元特异性烯醇化酶）与更差的功能结局相关。多变量模型显示，在细胞因子基础上加入血清 NfL 提高了对不良结局的预测能力（曲线下面积 = 0.75）。相比之下，没有急性期生物标志物能预测 cNORSE 后癫痫，而后者与 SE 持续时间延长、磁共振成像异常以及需要更密集的治疗相关。在配对分析中，大多数血清细胞因子在慢性期恢复正常，特别是 IL-6、IL-10 和 IL-1β，尽管 20% 的患者出现了新的适应性免疫紊乱（IL-17A、IL-12p70、TNFα）。在 cNORSE 后患者中未观察到先天性细胞因子的慢性升高。相反，cNORSE 后癫痫患者中年龄校正后 NfL 水平升高的频率（64%）高于脑炎患者（45%）和 TLE-HS 患者（20%）（p < 0.001），且 NfL 水平升高与功能结局不良相关（p = 0.019）。意义：先天性免疫激活是急性期 cNORSE 的标志，但在慢性期基本消退，这说明持续的先天性炎症并非 cNORSE 后癫痫的驱动因素。相比之下，持续升高的 NfL 水平提示存在持续的轴突损伤，可能导致不良结局。整合炎症和神经轴突损伤生物标志物可能改善风险分层并指导长期管理。

### 第二部分 AI 大师评价

本研究深入探讨了隐源性新发难治性癫痫持续状态（cNORSE）向耐药性癫痫演变的生物学机制，重点对比了急性期与慢性期的免疫状态和轴突损伤指标。研究揭示了急性期先天免疫激活与功能结局的相关性，并首次明确指出慢性期癫痫并非由持续性先天炎症驱动，而是与持续的神经轴突损伤（以NfL升高为标志）更为相关。该研究通过多中心队列和多病种对照，为cNORSE的风险分层和长期管理提供了关键的生物标志物证据。局限性在于部分适应性免疫紊乱的临床意义仍需在更大规模的前瞻性队列中进一步阐明。

---

## 2. 2010年至2025年间欧洲药品管理局癫痫药物研发临床指南的演变：国际抗癫痫联盟监管事务工作组的对比分析

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41697268)
**期刊：** Epilepsia
**PMID：** 41697268
**DOI：** 10.1002/epi.70152

### 第一部分 原文与翻译

**英文原标题：** Evolution of the European Medicines Agency clinical guidelines for epilepsy drug development between 2010 and 2025: A comparative analysis by the ILAE Task Force on Regulatory Affairs.

> **英文摘要：**
> OBJECTIVE: The latest European Medicines Agency (EMA) guideline on the clinical investigation of medicines to treat epileptic disorders was adopted by the EMA Committee for Medicinal Products for Human Use in 2025. We compared this guideline with the previous version (2010), highlighting areas where significant revisions were introduced. METHODS: The 2025 and 2010 versions of the guideline were systematically analyzed to identify significant modifications. RESULTS: The latest EMA guideline incorporated terminology from the 2017 International League Against Epilepsy (ILAE) classification of seizures and epilepsy and the 2022 classification of syndromes and replaced the older term "antiepileptic drug (AED)" with "antiseizure medication (ASM)." Recommendations for add-on studies in common epilepsies have remained substantially unchanged, the main revision being the acceptability of the time-to-event design also for confirmatory trials, provided it is not the only design in the clinical development plan. A major novelty is the feasibility of extrapolating data from add-on trials to the monotherapy indication, provided specific conditions are met. Guidance on pediatric ASM development has been expanded, addressing extrapolation of efficacy from data in adults and older children and options for studies in developmental and epileptic encephalopathies and other rare epilepsies. Compared with the previous guideline, greater emphasis is placed on nonseizure outcomes, including functional, quality of life, and patient-reported outcomes. Two new sections have been introduced, addressing studies in neonates and clinical trials in status epilepticus and other seizure emergencies. Options for innovative designs, including registry-based studies, are also discussed in situations where randomized controlled trials are unfeasible. SIGNIFICANCE: The updated guideline reflects the changing scenario in epilepsy treatment development, with a greater focus on pediatric epilepsies, rare epilepsies, and other indications with high unmet needs. The updates also reflect the contribution during the consultation process by a wide range of stakeholders, including the ILAE Task Force on Regulatory Affairs.

> **中文摘要：**
> 目的：欧洲药品管理局（EMA）人用药品委员会于2025年通过了关于治疗癫痫疾病药物临床研究的最新指南。我们将该指南与2010年的旧版进行了对比，重点阐述了引入重大修订的领域。方法：对2025版和2010版指南进行了系统分析，以识别重大修改。结果：最新的EMA指南纳入了2017年国际抗癫痫联盟（ILAE）发作和癫痫分类以及2022年综合征分类的术语，并将旧术语“抗癫痫药物（AED）”替换为“抗发作药物（ASM）”。针对常见癫痫的加用治疗研究建议基本保持不变，主要的修订在于接受将事件发生时间（time-to-event）设计用于确证性试验，前提是该设计并非临床开发计划中的唯一设计。一项重大的创新是在满足特定条件下，将加用试验的数据外推至单药治疗适应症的可行性。关于儿科ASM开发的指导有所扩展，涉及根据成人和大龄儿童数据进行疗效外推，以及针对发育性及癫痫性脑病和其他罕见癫痫的研究方案。与之前的指南相比，新版指南更加强调非发作性结局，包括功能性结局、生活质量和患者报告结局。新引入了两个章节，分别阐述了新生儿研究以及癫痫持续状态和其他癫痫发作急症的临床试验。在随机对照试验不可行的情况下，还讨论了包括基于登记库的研究在内的创新设计方案。意义：更新后的指南反映了癫痫治疗开发领域不断变化的情景，更加关注儿科癫痫、罕见癫痫和其他具有高度未满足需求适应症。这些更新还反映了包括ILAE监管事务工作组在内的广泛利益相关者在咨询过程中的贡献。

### 第二部分 AI 大师评价

本文由ILAE监管事务工作组撰写，系统对比了2025版与2010版EMA癫痫药物研发指南，揭示了监管思路从单一发作控制向关注综合功能结局的重大转变。研究核心发现包括接受加用试验数据外推至单药治疗、对儿科及罕见癫痫研究路径的显著扩展，以及引入了创新性的真实世界证据（如登记库研究）设计。该分析为制药企业和临床研究者提供了权威的法规演进视角，凸显了临床开发策略在满足未尽医疗需求和科学伦理平衡方面的最新进步。

---

## 3. 减量抗癫痫药物对局灶性癫痫脑电图动力学的影响：一项立体脑电图研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41697244)
**期刊：** Epilepsia
**PMID：** 41697244
**DOI：** 10.1002/epi.70149

### 第一部分 原文与翻译

**英文原标题：** Impact of antiseizure medication taper on electroencephalographic dynamics in focal epilepsy: A stereoelectroencephalographic study.

> **英文摘要：**
> OBJECTIVE: Tapering of the antiseizure medication dosage in the epilepsy monitoring unit can provoke seizures, but its effects on seizure dynamics remain poorly characterized. This study addresses three questions: (1) Does antiseizure medication tapering influence spatiotemporal dynamics of seizures? (2) Does the tapering rate affect these dynamics? (3) Does tapering have a similar effect on interictal epileptic discharges as it does on seizures? METHODS: Patients with drug-resistant epilepsy undergoing stereoelectroencephalographic (stereo-EEG) presurgical evaluations at Duke University Medical Center (n = 104) and the Montreal Neurological Institute and Hospital (n = 80) were screened. We included patients in whom the antiseizure medication dosage was tapered from the highest daily dosage (high dosage) to ≤ 50% (low dosage) during stereo-EEG monitoring, and at least one seizure from the same focus was recorded in both conditions. Using an intrapatient design, we compared seizure onset-zone, onset pattern, and propagation dynamics between the two conditions. Given the intrinsic seizure variability, comparisons were made between same-dosage and cross-dosage seizure pairs. We further assessed effects of tapering rates and examined the characteristics of interictal epileptiform discharges. RESULTS: Among 30 patients, the proportion of channels in the seizure onset zone did not differ between high-dosage and low-dosage conditions (7.25% vs. 8.95%, p = .50, d = -.04). Similarly, no differences were observed in the overlap ratio of seizure-onset regions (62% vs. 64%, p = .72, d = -.01), or the cross-correlation of seizure-onset patterns (.36 vs. .35, p = .54, d = .04) when comparing same-dosage versus cross-dosage seizure pairs. Conversely, seizures at low dosage involved more channels (40.71% vs. 81.49%, p = .001, d = -.39) and lasted longer (33.36 s vs. 74.30 s, p < .01, d = -.47). Tapering rate did not affect seizure dynamics. The mean interictal epileptiform discharge rate and number of propagation channels also remained unchanged. SIGNIFICANCE: Despite seizure exacerbation during antiseizure medication tapering, seizure-onset location remained stable. This supports the robustness of seizure-based localization even under reduced medication levels and rapid tapering regimens.

> **中文摘要：**
> 目的：在癫痫监测单元中减少抗癫痫药物剂量可以诱发癫痫发作，但其对癫痫发作动力学的影响尚不明确。本研究旨在探讨三个问题：（1）抗癫痫药物减量是否影响癫痫发作的时空动力学？（2）减量速率是否影响这些动力学？（3）减量对发作间期癫痫样放电的影响是否与对癫痫发作的影响相似？方法：筛选了在杜克大学医学中心（n = 104）和蒙特利尔神经病学研究所及医院（n = 80）接受立体脑电图（stereo-EEG）术前评估的难治性癫痫患者。我们将以下患者纳入研究：在 stereo-EEG 监测期间，其抗癫痫药物剂量从最高每日剂量（高剂量）减至 ≤ 50%（低剂量），且在两种条件下均记录到至少一次来自同一病灶的癫痫发作。采用患者自身对照设计，我们比较了两种条件下癫痫发作起始区、起始模式和传播动力学的差异。考虑到癫痫发作的内在变异性，我们在同剂量和跨剂量癫痫发作对之间进行了比较。我们进一步评估了减量速率的影响，并检查了发作间期癫痫样放电的特征。结果：在 30 名患者中，高剂量和低剂量条件下癫痫起始区涉及的通道比例没有差异（7.25% vs 8.95%，p = .50，d = -.04）。同样，在比较同剂量与跨剂量癫痫发作对时，癫痫起始区域的重叠率（62% vs 64%，p = .72，d = -.01）或癫痫起始模式的互相关性（.36 vs .35，p = .54，d = .04）也均未观察到差异。相反，低剂量下的癫痫发作涉及更多通道（40.71% vs 81.49%，p = .001，d = -.39）且持续时间更长（33.36 s vs 74.30 s，p < .01，d = -.47）。减量速率不影响癫痫动力学。平均发作间期癫痫样放电率和传播通道数量也保持不变。结论：尽管在抗癫痫药物减量期间癫痫发作有所加重，但癫痫起始位置保持稳定。这支持了即使在药物水平降低和快速减量方案下，基于癫痫发作定位的稳健性。

### 第二部分 AI 大师评价

本研究通过对耐药性癫痫患者进行立体脑电图（SEEG）监测，系统分析了抗癫痫药物减量对癫痫动力学的影响。研究发现，虽然药物减量会导致癫痫发作的范围扩大且持续时间延长，但核心的癫痫起始区（SOZ）及其起始模式在时空分布上表现出高度的稳定性。这一发现极具临床指导意义，因为它证实了临床常用的通过减药诱发发作来定位致痫灶的方法是可靠且稳健的，即使在快速减药的情况下，定位结果依然可信。

---

## 4. 极度隐源性新发难治性癫痫持续状态/热性感染相关癫痫综合征：深度神经炎症和神经元损伤的证据

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41697173)
**期刊：** Epilepsia
**PMID：** 41697173
**DOI：** 10.1002/epi.70157

### 第一部分 原文与翻译

**英文原标题：** Extreme cryptogenic new onset refractory status epilepticus/febrile infection-related epilepsy syndrome: Evidence of profound neuroinflammation and neuronal injury.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

该文献深入探讨了极度隐源性新发难治性癫痫持续状态（NORSE）与热性感染相关癫痫综合征（FIRES）的病理生理基础。研究重点提供了关于深度神经炎症及继发性神经元损伤的实质性证据，揭示了免疫介导机制在这一罕见临床重症中的关键地位。该工作对于临床理解NORSE/FIRES的急性期损伤过程以及探索针对性的免疫调节治疗方案具有重要的学术参考价值。

---

## 5. 纵向丘脑记录中的节律与癫痫发作风险相关

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41697160)
**期刊：** Epilepsia
**PMID：** 41697160
**DOI：** 10.1002/epi.70148

### 第一部分 原文与翻译

**英文原标题：** Rhythms in longitudinal thalamic recordings are linked to seizure risk.

> **英文摘要：**
> OBJECTIVE: Seizure unpredictability remains a major clinical challenge for people with epilepsy. Previous works have shown that seizure risk is associated with circadian and multi-day cycles in both brain and physiological signals. However, it remains unclear whether neural activity from deep brain structures such as the anterior nucleus of the thalamus (ANT), the only U.S. Food and Drug Administration (FDA)-approved deep-brain stimulation (DBS) target for treating medication-resistant epilepsy, exhibits similar cyclic modulation related to seizures. This study aimed to assess whether long-term local field potential (LFP) recordings from the ANT exhibit circadian and multi-day cycles that are associated with seizures that could be used to support seizure forecasting in a retrospective approach. METHODS: Seven participants implanted with the Medtronic Percept PC system for ANT-DBS underwent continuous at-home LFP recording of theta/alpha (4-12 Hz) and self-reported seizure logs. Wavelet and Hilbert transforms were used to identify rhythmic cycles in LFPs. Circular statistics quantified seizure phase-locking to LFP cycles and patterns estimated from seizure diaries. Gaussian process regression (GPR) models were trained using the instantaneous phase and amplitude of these cycles to forecast short-term seizure risk. RESULTS: A total of 7.37 years of at-home LFP recordings were analyzed. All seven participants exhibited circadian and/or multi-day cycles in their ANT LFPs, with seizures significantly phase-locked to some of these cycles. Incorporating the instantaneous cycle amplitude improved seizure forecasting performance across all participants. Moreover, a substantial, although non-significant, positive correlation between circadian cycle power and seizure frequency was found in most participants, suggesting an elevated seizure risk when circadian cycles are stronger. SIGNIFICANCE: This study demonstrates that long-term LFP recordings from the ANT reflect rhythmic brain activity linked to seizure risk, and that cycle amplitude provides complementary information about seizure risk than the phase alone.

> **中文摘要：**
> 目的：癫痫发作的不可预测性仍然是癫痫患者面临的主要临床挑战。先前的研究已经表明，大脑和生理信号中的昼夜节律及多日周期与癫痫发作风险相关。然而，目前尚不清楚来自丘脑前核（ANT）等深部脑结构的神经活动是否也表现出与癫痫发作相关的类似周期性调节，而ANT是目前美国食品药品监督管理局（FDA）批准的唯一用于治疗药物难治性癫痫的深部脑刺激（DBS）靶点。本研究旨在评估ANT的长程局部场电位（LFP）记录是否表现出与癫痫发作相关的昼夜节律和多日周期，并探讨是否能通过回顾性方法利用这些节律来辅助癫痫发作预测。方法：七名植入美敦力 Percept PC 系统进行 ANT-DBS 治疗的受试者接受了持续的居家 LFP 记录（涵盖 theta/alpha 频段，4-12 Hz）并记录了自我报告的癫痫日志。使用小波变换和希尔伯特变换来识别 LFP 中的节律性周期。利用圆形统计学量化了癫痫发作与 LFP 周期以及根据癫痫日记估计的模式之间的相位锁定关系。使用这些周期的瞬时相位和振幅训练高斯过程回归（GPR）模型，以预测短期癫痫发作风险。结果：共分析了 7.37 年的居家 LFP 记录。所有七名受试者的 ANT LFP 均表现出昼夜节律和/或多日周期，且癫痫发作显著相位锁定于其中某些周期。在所有受试者中，纳入瞬时周期振幅均提高了癫痫预测性能。此外，在大多数受试者中发现昼夜节律功率与癫痫发作频率之间存在实质性但非显著的正相关，这表明当昼夜节律较强时，癫痫发作风险较高。意义：本研究证明，来自 ANT 的长程 LFP 记录反映了与癫痫发作风险相关的节律性大脑活动，并且周期振幅提供了比单纯相位更互补的癫痫风险信息。

### 第二部分 AI 大师评价

本研究利用 ANT-DBS 植入设备对 7 名患者进行了长达 7.37 年的居家监测，首次在临床关键靶点丘脑前核（ANT）中证实了神经活动存在与癫痫风险紧密关联的昼夜及多日节律。研究创新性地结合了希尔伯特变换与高斯过程回归模型，证明了周期振幅在提升癫痫回顾性预测性能中的关键作用，而非仅仅依赖相位信息。尽管样本量较小，但该成果为基于植入式感应设备的个性化癫痫风险预警提供了坚实的电生理学证据，对于优化难治性癫痫的神经调控治疗具有重要的临床转化价值。

---

## 6. KPTN 相关疾病的临床谱系及小鼠模型中的神经发育发病机制

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41696790)
**期刊：** Annals of neurology
**PMID：** 41696790
**DOI：** 10.1002/ana.78159

### 第一部分 原文与翻译

**英文原标题：** The Clinical Spectrum and Neurodevelopmental Pathogenesis of KPTN-Related Disorder in a Mouse Model.

> **英文摘要：**
> OBJECTIVE: Pathogenic variants in Kaptin (KPTN) cause KPTN-related disorder (KRD). KPTN modulates mTOR signaling activation within the KICSTOR complex in response to cellular amino acid levels. We define the clinical spectrum and investigate the developmental pathogenesis of KRD. METHODS: We report the genotype and clinical phenotype of 71 KRD individuals (28 female subjects, ages 1 to 55 years) including 48 newly identified KRD individuals. The effects of Kptn knockout on brain development were assayed in vitro and in vivo. RESULTS: We defined 15 novel KPTN variants. Intellectual disability (ID) was identified in all KRD individuals. Macrocephaly and epilepsy were observed in 46% and 47%, respectively. Neuroimaging revealed megalencephaly but no overt structural abnormalities. Ketotic hypoglycemia and endocrinopathies were identified in KRD. Increased head size was detected in unaffected parents heterozygous for KPTN variants. Two KRD individuals with drug-resistant epilepsy were treated with the mTOR inhibitor sirolimus but did not exhibit improved seizure control. CRISPR/Cas9 Kptn knockout in vitro induced mTOR activation and an mTOR-dependent increase in cell size. Kptn-/- mice exhibited increased cortical mTOR signaling that was reduced by rapamycin. Heterotopic neurons were identified in the subcortical white matter in the Kptn -/- mouse. Focal CRISPR/Cas9 Kptn knockout in cortex via in utero electroporation resulted in white matter heterotopic neurons. Electroencephalogram (EEG) did not detect ictal or inter-ictal abnormalities. INTERPRETATION: KRD is a multisystem neurodevelopmental disorder associated with ID, macrocephaly, epilepsy, mTOR signaling hyperactivation, and in a mouse model, subtle structural alterations in cerebral cortical cytoarchitecture. ANN NEUROL 2026.

> **中文摘要：**
> 目的：Kaptin (KPTN) 基因的致病变异会导致 KPTN 相关疾病 (KRD)。KPTN 通过 KICSTOR 复合物调节 mTOR 信号通路的激活，以响应细胞内的氨基酸水平。本研究旨在定义 KRD 的临床谱系并研究其发育发病机制。方法：我们报道了 71 名 KRD 患者（28 名女性，年龄在 1 至 55 岁之间）的基因型和临床表型，其中包括 48 名新确诊的 KRD 患者。在体内和体外实验中评估了 Kptn 敲除对大脑发育的影响。结果：我们定义了 15 个新的 KPTN 变异。在所有 KRD 患者中均发现了智力障碍 (ID)。分别在 46% 和 47% 的患者中观察到大头畸形和癫痫。神经影像学显示巨脑畸形，但没有明显的大体结构异常。在 KRD 中还发现了酮症性低血糖和内分泌疾病。在携带 KPTN 变异杂合子的未受累父母中也检测到了头围增大。两名患有难治性癫痫的 KRD 患者接受了 mTOR 抑制剂西罗莫司治疗，但未表现出癫痫控制的改善。体外 CRISPR/Cas9 Kptn 敲除诱导了 mTOR 激活以及 mTOR 依赖性的细胞体积增大。Kptn-/- 小鼠表现出皮质 mTOR 信号增强，雷帕霉素可减轻这一现象。在 Kptn-/- 小鼠的皮质下白质中发现了异位神经元。通过子宫内电穿孔在皮质中进行的局部 CRISPR/Cas9 Kptn 敲除导致了白质异位神经元。脑电图 (EEG) 未检测到发作期或发作间期的异常。解释：KRD 是一种多系统神经发育障碍，与智力障碍、大头畸形、癫痫、mTOR 信号过度激活有关，且在小鼠模型中表现为大脑皮质细胞结构的细微结构改变。ANN NEUROL 2026。

### 第二部分 AI 大师评价

该研究通过对71例病例的深入分析，显著扩展了KPTN相关疾病（KRD）的临床和基因表型谱，明确了其作为一种多系统神经发育障碍的特征。研究结合临床观察与小鼠模型，证实了KPTN缺失导致的mTOR通路过度激活是其核心致病机制，并揭示了皮质下白质神经元异位这一关键的神经解剖学改变。尽管西罗莫司在初步临床尝试中对难治性癫痫疗效有限，但该研究为理解mTOR通路在脑发育中的作用及相关疾病的精准诊断提供了重要依据。

---

速递结束，祝您工作愉快！